In the News / Health


Groups Encourage Government to Do More to Prevent Opioid Addiction

Letter Bemoans Government-Issued Guidance that Fails to Incentivize Utilization of Non-Opioid Approaches

View More on PR Newswire

Venn Strategies Advocates Opioid Alternatives

Addiction prevention coalition Voices for Non-Opioid Choices has retained political and public affairs shop Venn Strategies to handle health issues on Capitol Hill.

View More on O'Dwyer's

Increasing Patient Access to Non-Opioid Pain Management Therapies

In 2016, of the 115 Americans who died each day from an opioid overdose, nearly half were using prescription opioid medications. Studies have estimated that just a 10% reduction in surgery-related opioid prescribing in the U.S. would result in 300,000 fewer people each year transitioning to long-term use and make 332 million fewer opioid pills available for potential diversion and misuse.

View More on downloadable PDF

Venn Health Team Adds Bipartisan Talent

Venn Strategies, LLC, a leading national public affairs and government relations firm, announced several key hires today, including incoming Vice President JoHannah Torkelson and new Senior Associate Michelle Seger.

View More

Venn Senior Team Grows With Addition of Top American Pharmacists Association Lobbyist

Venn Strategies, LLC, a leading national public affairs and government relations firm, announced today that Michael Spira has joined the firm as a Vice President. Spira brings more than fifteen years of political and policy experience, having most recently served as a senior lobbyist at the American Pharmacist Association.  He was previously Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO).

View More

More Sunshine on 340B Good for Patients | Commentary

In his recent opinion piece, Ascension Health CEO Robert Henkel pleads with Congress not to tinker with the 340B Drug Discount Program (“Placing the Health and Well Being of Patients First”, Roll Call, July 16). The program was created in 1992 to benefit medically underserved patients in the outpatient setting, but it has grown into a lucrative opportunity for many disproportionate share hospitals (DSH).

View More on Roll Call

Studies show Alarming Trend

A study released last week by the Berkeley Research Group (BRG) draws a troubling picture of how the 340B drug discount program – created to ensure that medically underserved patients have access to hospital outpatient drugs – not only is benefiting hospitals more than the patients themselves, but in fact may also be driving some hospitals to make business decisions solely in the interest of maximizing financial returns. Both Congress and regulators have an opportunity to put the program back on the right track.

View More on The Hill

Hospitals Finding Revenues with 340B

In 1992, the federal government told drugmakers they had to give steep discounts to hospitals that treat a large percentage of poor patients.

The law got bipartisan support and it was a boon for hospitals and the federal government. In the decades that followed, the discount program has grown by leaps and bounds.

View More on NPR

Charity Care Strayed Too Far

More than two decades after Congress formally established the 340B program to ensure that vulnerable and uninsured patients would have access to prescription medicines, it is increasingly clear that needy patients are not always the ones reaping the benefits of this important program.

View More on The Hill

CBO Scoring Misses Billions of Dollars in Potential Long-Term Savings from Effective Obesity Prevention Policies, According to New Study

Current methods for estimating the costs and savings of federal health legislation miss billions of dollars in potential long-term returns from effective obesity prevention policies, according to a new study released today by the Campaign to End Obesity. Changing the way cost estimates are created would give policymakers a clearer picture of costs and savings, the report concludes.

View More

Silverman Praises Healthy Choices Act

The Campaign to End Obesity is applauding legislation introduced by House Ways and Means Committee Democrat Ron Kind that includes a wide range of policies that aim to tackle the obesity epidemic. Kind’s Healthy Choices Act aims to improve prevention and treatment opportunities, increase access to physical activities for adults and children, expand nutrition training and realign transportation policies to promote healthier lifestyle, and support research.

View More

Electronic Newsletter of Pharmaceutical Technology: Regulatory Roundup: EMA Outlines Activities for 2011, and More

The European Medicines Agency (EMA) plans to focus on the implementation of its new pharmacovigilance legislation and the pending falsified drug legislation throughout 2011, according to its work program announcement on Feb. 11, 2011.

View More